Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 04 10; 41(11):1992-1998.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Humans
Lung Neoplasms
Pemetrexed
Platinum
Receptor Protein-Tyrosine Kinases

authors with profiles

Marina Chiara Garassino